Latest News and Press Releases

We have renewed our investigation into the fairness of the proposed sale of Silk Road Medical to Boston Scientific for $27.50 per share.

We are investigating the fairness of the proposed sale of Terran Orbital to Lockheed Martin for $0.25 per share in cash.

We are investigating the fairness of the proposed sale of Revance Therapeutics to Crown Laboratories for $6.66 per share in cash.

We are investigating the fairness of the proposed sale of RCM to TowerBrook and Clayton Dubilier & Rice for $14.30 per share in cash

We have filed a class action lawsuit on behalf of Morphic shareholders alleging securities claims in connection with the proposed sale to Eli Lilly.

We are investigating the fairness of the proposed sale of Cepton to Koito Manufacturing for $3.17 per share in cash.

We are investigating the fairness of the sale of Enstar Group Limited to Sixth Street for $338.00 per share in cash.

We are investigating the fairness of the proposed sale of Instructure to KKR for $23.60 per share in cash.

We are investigating the fairness of the proposed sale of Envestnet to Bain Capital for $63.15 per share in cash.

We are investigating Indivior for potential violations of the federal securities laws.